Heron Therapeutics, Inc. (HRTX) Stock Price

HRTXStock

$0.36−72.23%52W

Market Cap$68.54M

P/E—

PEG Ratio—

Div yield—

Beta1.64

HRTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-71.50%

Price vs S&P 500 (4W)35.03%

VGM Score40.29

Book Value / Share (Quarterly)$0.04

P/TBV (Annual)15.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)12.88%

Cash Flow / Share (Quarterly)$-0.06

Price vs S&P 500 (YTD)-84.16%

Gross Margin (TTM)70.07%

Net Profit Margin (TTM)-22.52%

EPS (TTM)$-0.19

10-Day Avg Trading Volume2.33M

EPS Excl Extra (TTM)$-0.19

Revenue Growth (5Y)11.82%

EPS (Annual)$-0.12

ROI (Annual)-13.03%

Gross Margin (Annual)73.31%

Net Profit Margin (5Y Avg)-106.84%

Cash / Share (Quarterly)$0.23

Revenue Growth QoQ (YoY)1.25%

ROA (Last FY)-7.89%

Revenue Growth TTM (YoY)0.99%

EBITD / Share (TTM)$-0.11

ROE (5Y Avg)-382.07%

Operating Margin (TTM)-14.69%

Cash Flow / Share (Annual)$-0.15

P/B Ratio9.92x

P/B Ratio (Quarterly)11.69x

Net Income / Employee (Annual)$-157,800

EV / Revenue (TTM)1.26x

Net Interest Coverage (TTM)-1.64x

ROA (TTM)-13.57%

EV / EBITDA (TTM)80.84x

EPS Incl Extra (Annual)$-0.12

Current Ratio (Annual)2.48x

Quick Ratio (Quarterly)1.44x

3-Month Avg Trading Volume2.78M

52-Week Price Return-72.23%

Revenue / Employee (TTM)$1,181,100

Tangible BV / Share (Quarterly)$-0.20

P/S Ratio (Annual)0.44x

Asset Turnover (Annual)0.61x

52-Week High$1.58

Operating Margin (5Y Avg)-103.72%

EPS Excl Extra (Annual)$-0.12

CapEx CAGR (5Y)-45.85%

Tangible BV CAGR (5Y)-36.47%

26-Week Price Return-61.60%

Quick Ratio (Annual)1.42x

13-Week Price Return-23.31%

Total Debt / Equity (Annual)9.81x

Current Ratio (Quarterly)2.49x

Enterprise Value$190.47M

Revenue / Share Growth (5Y)-0.97%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)-56.22%

Revenue / Employee (Annual)$1,210,200

Inventory Turnover (Annual)0.57x

Pretax Margin (Annual)-13.04%

Cash / Share (Annual)$0.25

3-Month Return Std Dev101.76%

Gross Margin (5Y Avg)58.20%

Net Income / Employee (TTM)$-266,000

ROE (Last FY)-140.90%

Net Interest Coverage (Annual)0.61x

EPS Basic Excl Extra (Annual)$-0.12

P/FCF (TTM)51.49x

Receivables Turnover (TTM)1.78x

Total Debt / Equity (Quarterly)20.65x

EPS Incl Extra (TTM)$-0.19

Receivables Turnover (Annual)1.84x

ROI (TTM)-22.33%

P/S Ratio (TTM)0.45x

Pretax Margin (5Y Avg)-106.84%

Revenue / Share (Annual)$0.93

Tangible BV / Share (Annual)$0.11

Forward P/E100.01x

Price vs S&P 500 (52W)-87.76%

Year-to-Date Return-72.23%

5-Day Price Return-13.14%

EPS Normalized (Annual)$-0.12

ROA (5Y Avg)-41.62%

Net Profit Margin (Annual)-13.04%

Month-to-Date Return15.15%

Cash Flow / Share (TTM)$-0.93

EBITD / Share (Annual)$-0.07

Operating Margin (Annual)-8.96%

LT Debt / Equity (Annual)9.81x

ROI (5Y Avg)-73.08%

LT Debt / Equity (Quarterly)20.65x

EPS Basic Excl Extra (TTM)$-0.19

P/B Ratio (Annual)16.63x

Inventory Turnover (TTM)0.55x

Pretax Margin (TTM)-22.52%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-25.99%

Beta1.64x

P/FCF (Annual)7.62x

Revenue / Share (TTM)$0.79

ROE (TTM)-300.90%

52-Week Low$0.26

vGradeC

gGradeC

mGradeD

vgmGradeC

HRTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.02	-$0.03	-50.00%(-$0.01)
Q1 2026	May 11, 2026	-$0.02	-$0.04	-100.00%(-$0.02)
Q4 2025	Feb 26, 2026	-$0.03	-$0.02	+33.33%(+$0.01)
Q3 2025	Nov 4, 2025	-$0.01	-$0.04	-170.82%(-$0.02)
Q2 2025	Aug 8, 2025	-$0.01	-$0.02	-100.00%(-$0.01)

HRTX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.11

4.00

2.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
HRTXHeron Therapeutics, Inc.	C	C	D	0.5x	1.0%	70.1%	—	$0.36
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Heron Therapeutics, Inc.

Heron Therapeutics is a commercial-stage biopharmaceutical company with a portfolio of marketed products including APONVIE, SUSTOL, ZYNRELEF, and CINVANTI. The company develops innovative treatments to address unmet patient needs.

HRTX Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.03

Revenue estimate$37.50M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

PTHSPelthos Therapeutics Inc.Biological Products
OKYOOKYO Pharma Limited Ordinary SharesBiological Products
CRDFCardiff Oncology, Inc. Common StockBiological Products
CGTXCognition Therapeutics, Inc. Common StockBiological Products
CSBRChampions Oncology, Inc.Biological Products
SLSNSolesence, Inc. Common StockCosmetics & Toiletries
CITRCitroTech Inc.Chemicals
ZTEKZentek Ltd. Common StockIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

2.3

Sell

Consensus rating

52-Week Range

Low$0.26

High$1.58